Abbott Spins Off Pharma Business - Analyst Blog

A generic image of a pen next to a pile of coins
Credit: Shutterstock photo

AbbottLaboratories ( ABT ) recently announced that the company has separated its research-based pharmaceuticals business by creating a new company - AbbVie ( ABBV ).

The decision to spin off the business was taken back in October 2011 when Abbott decided to separate its business into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals.

The research-based pharmaceutical company, AbbVie, includes proprietary pharmaceuticals and biologics including products like Humira, Lupron, Synagis, Kaletra, Creon and Synthroid. The business generated sales of approximately $17.4 billion in 2011 while sales are expected to exceed $18 billion in 2012.

The diversified medical products company, with estimated sales of about $23 billion, includes Abbott's branded generic pharmaceutical, devices, diagnostic and nutritional businesses.

The existing shareholders of the parent company generally get new shares in the subsidiary when the company spins off one of its business into a separate company. The subsidiary becomes a separate legal entity with its own management team and board of directors.

On Nov. 28, 2012, Abbott declared a special dividend distribution of all outstanding shares of AbbVie common stock. The shareholders of Abbott received one share of AbbVie common stock on Jan. 1, 2013 for every one share of Abbott common shares held as of close of business on Dec. 12, 2012.

The company is looking to ensure growth through this split. We are positive on the split which should allow the two separate entities to perform in a more focused manner.

As expected, the news was well received by investors with Abbott's shares increasing 2.27% in regular trading to close at $32.05.

We currently have a Neutral recommendation on Abbott, which carries a Zacks #3 Rank (Hold). Right now, Allergan, Inc. ( AGN ) looks attractive with a Zacks #2 Rank (Buy).

(ABBV): ETF Research Reports

ABBOTT LABS (ABT): Free Stock Analysis Report

ALLERGAN INC (AGN): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More